Bingen has new competition: Swiss pharma giant Novartis received FDA approval Friday for a spinal muscular atrophy drug that can stave off and potentially cure the disease with a single treatment. The approval sent Biogen’s stock down one percent as of 1 p.m.

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/05/24/biogen-loses-edge-on-blockbuster-rare-disease.html?ana=RSS&s=article_search